B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and...B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and immune escape of bladder cancer, B7-H1 expression in 50 cases of bladder cancer was detected by using immunohistochemical method. Survival curves were con- structed using the Kaplan-Meier method and independent prognostic factors were evaluated using the Cox regression model. Our results showed that the positive rate of B7-H1 immunostaining in normal bladder tissue and bladder cancer was 0 and 72% respectively. The expression of B7-H1 was strongly associated with the pathological grade, clinical stage and recurrence （P〈0.05）. The survival rate was significantly lower in patients with B7-H1 positive group than in those with B7-H1 negative group and multi-variable analysis revealed that B7-H1 could be regarded as an independent factor in evaluating the prognosis of bladder cancer. It is concluded that the expression of B7-H1 is strongly associated with neoplastic progression and prognosis of bladder cancer. The manipulation of B7-H1 may become a beneficial target for immunotherapy in human bladder cancer.展开更多
Objective To determine the level of soluble B7-H1(s B7-H1)in serum of patients with colorectal cancer(CRC),and to investigate its clinical application value in CRC.Methods 152 cases of CRC,57 cases of benign colorecta...Objective To determine the level of soluble B7-H1(s B7-H1)in serum of patients with colorectal cancer(CRC),and to investigate its clinical application value in CRC.Methods 152 cases of CRC,57 cases of benign colorectal diseases and 59 healthy subjects were enrolled.ELISA was used to determine the s B7-H1 level in serum.The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 72-4(CA72-4)were determined by electrochemiluminescence.The level of carbohydrate antigen 50(CA-50)was determined by chemiluminescence.ROC curve was used to evaluate the diagnostic efficiency of s B7-H1 alone or combined with other tumor markers in CRC.It also analyzed the correlation between serum s B7-H1 level and some clinicopathological characteristics including tumor location,depth of invasion,lymph node metastasis status,distant metastasis status and tumor stages.Results(1)The differences of s B7-H1 level among CRC group,colorectal benign disease group and healthy control group(compared with each other respectively)were statistically significant(P<0.001).Levels of CEA,CA19-9,CA72-4 and CA-50 were significantly different between CRC group and benign colorectal disease group(P<0.05),while there was no significant difference between the benign colorectal disease group and the healthy control group(P>0.05).(2)The diagnosis ability of s B7-H1,CEA,CA19-9,CA72-4,and CA-50 were determined by the area under curve(AUC),which was 0.730,0.772,0.639,0.663 and 0.635,respectively.The combination of s B7-H1 and CEA showed the best effect,and the AUC reached 0.831.(3)There was no significant correlation between the levels of s B7-H1 and CEA,or CA19-9,CA72-4,CA-50.(4)Immunohistochemistry result showed that the positive rate of CRC group was 52%,while that of benign disease group was 6.3%.The difference of the positive rate between the two groups was statistically significant(P<0.01).And there was a significant correlation between the positive rate of s B7-H1 level in serum and tumor tissues of CRC patients(P<0.05).(5)The serum s B7-H1 level in CRC patients was related to lymph node metastasis status(P<0.05).But there was no relationship between s B7-H1 level and other clinicopathological characteristics(including tumor location,depth of invasion,distant metastasis status and tumor stage)(P>0.05).Conclusion Serum s B7-H1 has a high clinical application value and could serve as a new tumor marker in CRC.展开更多
Human glioblastoma is a highly lethal tumor that is known for its immune inhibitory capabilities.B7-homologue l(B7-H 1),a recently identified homologue of B7.1/2(CD80/86),has been described to exert costimulatoryand i...Human glioblastoma is a highly lethal tumor that is known for its immune inhibitory capabilities.B7-homologue l(B7-H 1),a recently identified homologue of B7.1/2(CD80/86),has been described to exert costimulatoryand immune regulatory functions.We investigated the expression and the functional activity of B7-H 1 in humanglioma cells in vitro and in vivo.Although lacking B7.1/2(CD80/86),all 12 glioma cel1 1ines constitutivelyexpressed B7-H1 mRNA and protein.Exposure to IFN-gamma strongly enhanced B7-H 1 expression.Im-展开更多
The data from in vitro and animal experiment study has showed that costimulaory molecule B7 1 plays an important role in antitumor immunity In the present study, B7 1 expression was ob...The data from in vitro and animal experiment study has showed that costimulaory molecule B7 1 plays an important role in antitumor immunity In the present study, B7 1 expression was observed in 130 samples from a veriety of human malignancies by using immunocytochemistry, in situ hybridization and RT PCR combined with dot hybridization and B7 1 specific Mab and probe The results demonstrated B7 1 expression on tumor cells in 76 cases at both protein and mRNA level Forty two specimens were stained with B7 1 HLA ABC and HLA DR Mab and 26 showed that the three antibodies used all were positive Together with the achievement in tumor antigen study, the present findings imply that in most tumors (if not all) the tumor cells have all the requisite element to elicit anti tumor rejection response, the heterogeneous mechanism for tumor escape from immunosurvillance should be emphasized展开更多
基金supported by a grant from Hubei Provin-cial Science and Technology Key Program Foundation of China (No. 2007AA402C60).
文摘B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and immune escape of bladder cancer, B7-H1 expression in 50 cases of bladder cancer was detected by using immunohistochemical method. Survival curves were con- structed using the Kaplan-Meier method and independent prognostic factors were evaluated using the Cox regression model. Our results showed that the positive rate of B7-H1 immunostaining in normal bladder tissue and bladder cancer was 0 and 72% respectively. The expression of B7-H1 was strongly associated with the pathological grade, clinical stage and recurrence （P〈0.05）. The survival rate was significantly lower in patients with B7-H1 positive group than in those with B7-H1 negative group and multi-variable analysis revealed that B7-H1 could be regarded as an independent factor in evaluating the prognosis of bladder cancer. It is concluded that the expression of B7-H1 is strongly associated with neoplastic progression and prognosis of bladder cancer. The manipulation of B7-H1 may become a beneficial target for immunotherapy in human bladder cancer.
文摘Objective To determine the level of soluble B7-H1(s B7-H1)in serum of patients with colorectal cancer(CRC),and to investigate its clinical application value in CRC.Methods 152 cases of CRC,57 cases of benign colorectal diseases and 59 healthy subjects were enrolled.ELISA was used to determine the s B7-H1 level in serum.The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 72-4(CA72-4)were determined by electrochemiluminescence.The level of carbohydrate antigen 50(CA-50)was determined by chemiluminescence.ROC curve was used to evaluate the diagnostic efficiency of s B7-H1 alone or combined with other tumor markers in CRC.It also analyzed the correlation between serum s B7-H1 level and some clinicopathological characteristics including tumor location,depth of invasion,lymph node metastasis status,distant metastasis status and tumor stages.Results(1)The differences of s B7-H1 level among CRC group,colorectal benign disease group and healthy control group(compared with each other respectively)were statistically significant(P<0.001).Levels of CEA,CA19-9,CA72-4 and CA-50 were significantly different between CRC group and benign colorectal disease group(P<0.05),while there was no significant difference between the benign colorectal disease group and the healthy control group(P>0.05).(2)The diagnosis ability of s B7-H1,CEA,CA19-9,CA72-4,and CA-50 were determined by the area under curve(AUC),which was 0.730,0.772,0.639,0.663 and 0.635,respectively.The combination of s B7-H1 and CEA showed the best effect,and the AUC reached 0.831.(3)There was no significant correlation between the levels of s B7-H1 and CEA,or CA19-9,CA72-4,CA-50.(4)Immunohistochemistry result showed that the positive rate of CRC group was 52%,while that of benign disease group was 6.3%.The difference of the positive rate between the two groups was statistically significant(P<0.01).And there was a significant correlation between the positive rate of s B7-H1 level in serum and tumor tissues of CRC patients(P<0.05).(5)The serum s B7-H1 level in CRC patients was related to lymph node metastasis status(P<0.05).But there was no relationship between s B7-H1 level and other clinicopathological characteristics(including tumor location,depth of invasion,distant metastasis status and tumor stage)(P>0.05).Conclusion Serum s B7-H1 has a high clinical application value and could serve as a new tumor marker in CRC.
文摘Human glioblastoma is a highly lethal tumor that is known for its immune inhibitory capabilities.B7-homologue l(B7-H 1),a recently identified homologue of B7.1/2(CD80/86),has been described to exert costimulatoryand immune regulatory functions.We investigated the expression and the functional activity of B7-H 1 in humanglioma cells in vitro and in vivo.Although lacking B7.1/2(CD80/86),all 12 glioma cel1 1ines constitutivelyexpressed B7-H1 mRNA and protein.Exposure to IFN-gamma strongly enhanced B7-H 1 expression.Im-
文摘The data from in vitro and animal experiment study has showed that costimulaory molecule B7 1 plays an important role in antitumor immunity In the present study, B7 1 expression was observed in 130 samples from a veriety of human malignancies by using immunocytochemistry, in situ hybridization and RT PCR combined with dot hybridization and B7 1 specific Mab and probe The results demonstrated B7 1 expression on tumor cells in 76 cases at both protein and mRNA level Forty two specimens were stained with B7 1 HLA ABC and HLA DR Mab and 26 showed that the three antibodies used all were positive Together with the achievement in tumor antigen study, the present findings imply that in most tumors (if not all) the tumor cells have all the requisite element to elicit anti tumor rejection response, the heterogeneous mechanism for tumor escape from immunosurvillance should be emphasized
